- Email: [email protected]
Re: Preoperative Erectile Function is the Only Predictor of the Use of a High Number of Phosphodiesterase Type-5 Inhibitors after Bilateral Nerve-Sparing Radical Prostatectomy
MALE AND FEMALE SEXUAL FUNCTION AND DYSFUNCTION; ANDROLOGY
1773
Re: Preoperative Erectile Function is the Only Predictor of the Use of a High Number of Phosphodiesterase Type-5 Inhibitors after Bilateral Nerve-Sparing Radical Prostatectomy G. Gandaglia, A. Gallina, N. Suardi, F. Abdollah, N. Passoni, M. Bianchi, E. Zaffuto, A. Nini, D. Vizziello, A. Salonia, F. Montorsi and A. Briganti Department of Urology, Urological Research Institute, University Vita-Salute San Raffaele and San Raffaele Scientific Institute, San Raffaele Hospital, Milan, Italy Int J Impot Res 2014; Epub ahead of print.
Abstract available at http://jurology.com/ Editorial Comment: The aim of this study was to identify predictors of increased (at least once weekly) use of phosphodiesterase type 5 inhibitors (PDE5-Is) postoperatively among 184 patients taking proerectile medications on demand. At a mean followup of 22.7 months 116 patients (63%) recovered erectile function (EF). Overall EF recovery rates at 1 and 2-year followup were 47.3% and 65.4%, respectively. A total of 43 patients (23.4%) used PDE5-Is at least once weekly. Preoperative EF was the only predictor of increased use of PDE5-Is after bilateral nerve sparing radical prostatectomy. This is another in a series of studies demonstrating that patients who undergo bilateral nerve sparing prostatectomy seem to be able to recover erectile function following surgery. Other patients had modest responses to PDE5-I use. Allen D. Seftel, MD
Suggested Reading Harris CR, Punnen S and Carroll PR: Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. J Urol 2013; 190: 981. Pastuszak AW, Pearlman AM, Lai WS et al: Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639.
Re: Predictors of Sexual Dysfunction Incidence and Remission in Men S. A. Martin, E. Atlantis, K. Lange, A. W. Taylor, P. O’Loughlin and G. A. Wittert; Florey Adelaide Male Ageing Study Freemasons Foundation Centre for Men’s Health and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia J Sex Med 2014; 11: 1136e1147.
Abstract available at http://jurology.com/ Editorial Comment: The authors provide fascinating data. Erectile dysfunction and low sexual desire are reviewed. The data support previously held notions of the causation of erectile dysfunction and low desire, and to some degree reaffirm the historical etiologies. These data open the door for many interesting questions and further study. Allen D. Seftel, MD
Re: A Critical Evaluation of Salivary Testosterone as a Method for the Assessment of Serum Testosterone T. Fiers, J. Delanghe, G. T’Sjoen, E. Van Caenegem, K. Wierckx and J. M. Kaufman Clinical Chemistry and Endocrinology, Ghent University Hospital, Ghent, Belgium Steroids 2014; 86: 5e9.
1773
Re: Preoperative Erectile Function is the Only Predictor of the Use of a High Number of Phosphodiesterase Type-5 Inhibitors after Bilateral Nerve-Sparing Radical Prostatectomy G. Gandaglia, A. Gallina, N. Suardi, F. Abdollah, N. Passoni, M. Bianchi, E. Zaffuto, A. Nini, D. Vizziello, A. Salonia, F. Montorsi and A. Briganti Department of Urology, Urological Research Institute, University Vita-Salute San Raffaele and San Raffaele Scientific Institute, San Raffaele Hospital, Milan, Italy Int J Impot Res 2014; Epub ahead of print.
Abstract available at http://jurology.com/ Editorial Comment: The aim of this study was to identify predictors of increased (at least once weekly) use of phosphodiesterase type 5 inhibitors (PDE5-Is) postoperatively among 184 patients taking proerectile medications on demand. At a mean followup of 22.7 months 116 patients (63%) recovered erectile function (EF). Overall EF recovery rates at 1 and 2-year followup were 47.3% and 65.4%, respectively. A total of 43 patients (23.4%) used PDE5-Is at least once weekly. Preoperative EF was the only predictor of increased use of PDE5-Is after bilateral nerve sparing radical prostatectomy. This is another in a series of studies demonstrating that patients who undergo bilateral nerve sparing prostatectomy seem to be able to recover erectile function following surgery. Other patients had modest responses to PDE5-I use. Allen D. Seftel, MD
Suggested Reading Harris CR, Punnen S and Carroll PR: Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. J Urol 2013; 190: 981. Pastuszak AW, Pearlman AM, Lai WS et al: Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639.
Re: Predictors of Sexual Dysfunction Incidence and Remission in Men S. A. Martin, E. Atlantis, K. Lange, A. W. Taylor, P. O’Loughlin and G. A. Wittert; Florey Adelaide Male Ageing Study Freemasons Foundation Centre for Men’s Health and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia J Sex Med 2014; 11: 1136e1147.
Abstract available at http://jurology.com/ Editorial Comment: The authors provide fascinating data. Erectile dysfunction and low sexual desire are reviewed. The data support previously held notions of the causation of erectile dysfunction and low desire, and to some degree reaffirm the historical etiologies. These data open the door for many interesting questions and further study. Allen D. Seftel, MD
Re: A Critical Evaluation of Salivary Testosterone as a Method for the Assessment of Serum Testosterone T. Fiers, J. Delanghe, G. T’Sjoen, E. Van Caenegem, K. Wierckx and J. M. Kaufman Clinical Chemistry and Endocrinology, Ghent University Hospital, Ghent, Belgium Steroids 2014; 86: 5e9.